Organ Preservation for Nasal Cavity Cancers Using Definitive Radiotherapy for Avoiding Rhinectomy
Menée à l'aide de données 2002-2024 portant sur des patients atteints d'un cancer de la muqueuse nasale antérieure et ayant refusé une rhinotomie ou présentant une tumeur non résécable, cette étude analyse l'intérêt d'une radiothérapie définitive avec ou sans chimiothérapie
Standard management of anterior mucosal nasal cavity (NC) cancers involves rhinectomy and adjuvant radiotherapy (RT) with or without chemotherapy. Given the potential negative impacts on cosmesis and quality of life, we evaluated use of definitive RT with or without chemotherapy for patients who declined rhinectomy or had unresectable disease. In this cohort study, we retrospectively identified consecutive patients treated with definitive RT for anterior mucosal NC cancers without oncologic resection at Memorial Sloan Kettering Cancer Center (MSKCC) from 2002 to 2024. The study was approved by the institutional review board of the MSKCC with a waiver of informed consent due to retrospective methods and followed the STROBE reporting guideline. RT included intensity modulated RT (IMRT), IMRT with proton beam therapy (PBT) boost, or PBT alone. Local recurrence within the NC (LR) was estimated with cumulative incidence with death as a competing risk (details on analysis in the eMethods in Supplement 1). Univariable analyses were performed without multiple comparisons adjustments.
JAMA Oncology , résumé, 2025